Your browser doesn't support javascript.
loading
Localised rhabdomyosarcoma in infants (<12 months) and young children (12-36 months of age) treated on the EpSSG RMS 2005 study.
Slater, Olga; Gains, Jennifer E; Kelsey, Anna M; De Corti, Federica; Zanetti, Ilaria; Coppadoro, Beatrice; Jorgensen, Mette; Gallego, Soledad; Orbach, Daniel H; Glosli, Heidi; Cesen, Maja; Gaze, Mark N; Smeulders, Naima; Ferrari, Andrea; Jenney, Meriel; Minard-Colin, Veronique; Bisogno, Gianni; Merks, Johannes H M.
Afiliação
  • Slater O; Department of Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address: olga.slater@gosh.nhs.uk.
  • Gains JE; University College London Hospital NHS Foundation Trust, London, UK.
  • Kelsey AM; Department of Paediatric Histopathology, Royal Manchester Children's Hospital, Manchester, UK.
  • De Corti F; University of Padova, Paediatric Surgery Women's and Health Department, Padova, Italy.
  • Zanetti I; Istituto Oncologico Veneto IOV - IRCCS, Clinical Research Unit, Padua, Italy.
  • Coppadoro B; Istituto Oncologico Veneto IOV - IRCCS, Clinical Research Unit, Padua, Italy.
  • Jorgensen M; Department of Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Gallego S; Pediatric Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Orbach DH; SIREDO Oncology Center, Institute Curie, PSL University, Paris, France.
  • Glosli H; Department of Paediatric Research, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
  • Cesen M; University Hospital Ljubljana, Department of Paediatric Haematology and Oncology, Ljubljana, Slovenia.
  • Gaze MN; Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Smeulders N; Department of Urology, Great Ormond Street Hospital NHS Foundation Trust, London, UK.
  • Ferrari A; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
  • Jenney M; Department of Paediatric Oncology, Children's Hospital for Wales, Heath Park, Cardiff, United Kingdom.
  • Minard-Colin V; Department of Pediatric and Adolescent Oncology, INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Bisogno G; Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy.
  • Merks JHM; Princess Máxima Center for Paediatric Oncology, Utrecht, the Netherlands.
Eur J Cancer ; 160: 206-214, 2022 01.
Article em En | MEDLINE | ID: mdl-34865946
BACKGROUND: Infants (<12 months) with rhabdomyosarcoma have historically had poorer outcome than the older age groups. We present outcomes for infants and young children aged 12-36 months with localised rhabdomyosarcoma with a particular emphasis on infants. PATIENTS AND METHODS: All children less than 36 months of age enrolled on the EpSSG RMS 2005 study for localised disease are included. Treatment comprised chemotherapy, local surgery and/or radiation therapy adapted to risk group and age. Main outcome measures were event free survival (EFS) and overall survival (OS). RESULTS: Outcome data were available for 485/490 patients aged less than 36 months, 110 were infants. Infants received chemotherapy according to the risk group with no toxic deaths. Radiotherapy was delivered to 33.6% of infants and 63.5% of 12-36 months old, with respectively 41.7% and 22.2% receiving brachytherapy. Radical surgery was performed in 62% of infants and 57.1% of 12-36 months old. Median follow up for patients who are alive (n = 393) was 72.7 months (range 6.9-158.2). Five-year OS for infants was 88.4% (95%CI 80.3-93.2), which is significantly better than the OS in 12-36 months old patients of 78.0% (95%CI 73.2-82.0; p = 0.0204). Five-year EFS for infants was 72.5% (95%CI 62.8-80.0) compared with 66.1% (95%CI 61.0-70.7; p = 0.2663) for 12-36 months old. CONCLUSION: Infants treated on RMS 2005 achieved excellent EFS and OS. The EpSSG RMS 2005 chemotherapy regimen, combined with an increase in the application of adequate local therapy, improvements in imaging and supportive care and potentially favourable patients' characteristics may have contributed to these results.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma Limite: Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma Limite: Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Ano de publicação: 2022 Tipo de documento: Article